Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release an... ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Propafenone, and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. Mehr anzeigen
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer...
Alcami Announces CEO Transition PR Newswire DURHAM, N.C., Jan. 13, 2025 Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries DURHAM, N.C., Jan. 13, 2025...
For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024Rare...
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug...
PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer;...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.76 | 1.2749538668 | 59.61 | 60.99 | 57.08 | 139664 | 58.88800938 | CS |
| 4 | 6.74 | 12.5675927652 | 53.63 | 60.99 | 52.735 | 177691 | 57.22295297 | CS |
| 12 | 0.57 | 0.953177257525 | 59.8 | 60.99 | 52.5 | 231424 | 56.33847928 | CS |
| 26 | -0.43 | -0.707236842105 | 60.8 | 65.69 | 52.5 | 305498 | 58.07435946 | CS |
| 52 | 4.67 | 8.3842010772 | 55.7 | 70.81 | 52.5 | 229640 | 60.25854447 | CS |
| 156 | 22 | 57.3364607766 | 38.37 | 70.81 | 22.31 | 153814 | 52.46551358 | CS |
| 260 | -3.03 | -4.77917981073 | 63.4 | 70.81 | 22.31 | 131180 | 48.22604077 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
